Ország: Egyesült Államok
Nyelv: angol
Forrás: NLM (National Library of Medicine)
BUPROPION HYDROCHLORIDE (UNII: ZG7E5POY8O) (BUPROPION - UNII:01ZG3TPX31)
Mylan Institutional Inc.
ORAL
PRESCRIPTION DRUG
Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder (MDD), as defined by the Diagnostic and Statistical Manual (DSM). The efficacy of the immediate-release formulation of bupropion was established in two 4-week controlled inpatient trials and one 6-week controlled outpatient trial of adult patients with MDD. The efficacy of the sustained-release formulation of bupropion in the maintenance treatment of MDD was established in a long-term (up to 44 weeks), placebo-controlled trial in patients who had responded to bupropion in an 8-week study of acute treatment [see Clinical Studies (14.1)] . Bupropion hydrochloride extended-release tablets (XL) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder (SAD). The efficacy of bupropion hydrochloride extended-release tablets in the prevention of seasonal major depressive episodes was established in 3 placebo-controlled trials in a
Bupropion Hydrochloride Extended-Release Tablets, USP (XL) are available containing 150 mg or 300 mg of bupropion hydrochloride, USP. The 150 mg tablets are supplied as off-white to pale yellow, film-coated, round, unscored tablets with M over B8 imprinted in black ink on one side of the tablet and blank on the other side. They are available as follows: NDC 51079-047-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). The 300 mg tablets are supplied as off-white to pale yellow, film-coated, oval, unscored tablets with M B9 imprinted in black ink on one side of the tablet and blank on the other side. They are available as follows: NDC 51079-109-03 – Unit dose blister packages of 30 (3 cards of 10 tablets each). Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from light. Bupropion hydrochloride extended-release tablets (XL) may have an odor. PHARMACIST: Dispense a Medication Guide with each prescription.
Abbreviated New Drug Application
Mylan Institutional Inc. ---------- MEDICATION GUIDE Bupropion Hydrochloride Extended-Release Tablets, USP (XL) (bue proe' pee on hye'' droe klor' ide) IMPORTANT: Be sure to read the three sections of this Medication Guide. The first section is about the risk of suicidal thoughts and actions with antidepressant medicines; the second section is about the risk of changes in thinking and behavior, depression and suicidal thoughts or actions with medicines used to quit smoking; and the third section is entitled “What Other Important Information Should I Know About Bupropion Hydrochloride Extended-Release Tablets (XL)?” Antidepressant Medicines, Depression and Other Serious Mental Illnesses, and Suicidal Thoughts or Actions This section of the Medication Guide is only about the risk of suicidal thoughts and actions with antidepressant medicines. What is the most important information I should know about antidepressant medicines, depression and other serious mental illnesses, and suicidal thoughts or actions? 1. Antidepressant medicines may increase the risk of suicidal thoughts or actions in some children, teenagers, or young adults within the first few months of treatment. 2. Depression or other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a particularly high risk of having suicidal thoughts or actions. These include people who have (or have a family history of) bipolar illness (also called manic- depressive illness) or suicidal thoughts or actions. 3. How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member? 1. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is very important when an antidepressant medicine is started or when the dose is changed. 2. Call your healthcare provider right away to report new or sudden changes in mood, behavior, thoughts, or feelings. 3. Keep all follow-up visits with your healthcare provider as scheduled. Call the hea Olvassa el a teljes dokumentumot
BUPROPION HYDROCHLORIDE- BUPROPION HYDROCHLORIDE TABLET, FILM COATED, EXTENDED RELEASE MYLAN INSTITUTIONAL INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS (XL) SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS (XL). BUPROPION HYDROCHLORIDE EXTENDED-RELEASE TABLETS (XL), FOR ORAL USE INITIAL U.S. APPROVAL: 1985 WARNING: SUICIDAL THOUGHTS AND BEHAVIORS _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ INCREASED RISK OF SUICIDAL THINKING AND BEHAVIOR IN CHILDREN, ADOLESCENTS, AND YOUNG ADULTS TAKING ANTIDEPRESSANTS. MONITOR FOR WORSENING AND EMERGENCE OF SUICIDAL THOUGHTS AND BEHAVIORS. ( 5.1) RECENT MAJOR CHANGES Boxed Warning 05/2017 Warnings and Precautions, Neuropsychiatric Adverse Events and Suicide Risk in Smoking Cessation Treatment ( 5.2) 05/2017 INDICATIONS AND USAGE Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant, indicated for the treatment of major depressive disorder (MDD) and prevention of seasonal affective disorder (SAD). Periodically reevaluate long-term usefulness for the individual patient. ( 1) DOSAGE AND ADMINISTRATION Ge ne ral: Increase dose gradually to reduce seizure risk. ( 2.1, 5.3) Periodically reassess the dose and need for maintenance treatment. ( 2.2) Major Depressive Disorder: Starting dose: 150 mg once daily. Usual target dose: 300 mg once daily. ( 2.2) After 4 days, may increase the dose to 300 mg once daily. ( 2.2) Seasonal Affective Disorder: Initiate treatment in the autumn prior to onset of seasonal depressive symptoms. ( 2.3) Starting dose: 150 mg once daily. Usual target dose: 300 mg once daily. ( 2.3) After one week, may increase the dose to 300 mg once daily. ( 2.3) Continue treatment through the winter season. ( 2.3) Hepatic Impairment: Moderate to severe hepatic impairment: 150 mg every other day. ( 2.6) Mild hepatic impairment: Consider reduc Olvassa el a teljes dokumentumot